ArticleAnnals of surgical oncology2026
Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study.
Yonggang He et al.PubMed ↗Publisher ↗
No numbers read from the abstract.